Blue Jet Healthcare Ltd Plans ₹2,300 Crore Andhra Plant

Blue Jet Healthcare Ltd plans to invest up to ₹2,300 crore in a 102-acre greenfield pharmaceutical manufacturing facility at Rambilli Industrial Park in Andhra Pradesh, with phased operations targeted by FY2028-29. The project is designed to make pharmaceutical intermediates, APIs, high-intensity sweeteners and multipurpose chemistry products.

What is Blue Jet building in Andhra Pradesh?

Blue Jet is developing a greenfield advanced pharmaceutical intermediates and contract development and manufacturing organisation, or CDMO, facility in Rambilli Industrial Park, Anakapalli district, near Visakhapatnam. The foundation stone was laid on February 28, 2026, by Andhra Pradesh Minister for ITE&C, RTGS and HRD Nara Lokesh.

The site covers 102.48 acres, with reports also describing it as a 102-acre project. It is located in Phase II of Rambilli Industrial Park. The proposed plant will expand Blue Jet's manufacturing footprint beyond its existing operations and add capacity in specialty pharmaceutical and chemical products.

The project is planned as a multi-phase development. Blue Jet's board approved an initial investment of about ₹1,000 crore for Phase 1 through a resolution dated July 31, 2025. The larger investment potential of up to ₹2,300 crore remains subject to regulatory approvals, project milestones and further board clearances.

Which products will the Rambilli facility manufacture?

Blue Jet plans to manufacture complex pharmaceutical intermediates, active pharmaceutical ingredients, contrast media intermediates, high-intensity sweeteners and multipurpose chemistry products at the Rambilli facility. These are product categories that support both specialty chemical applications and pharmaceutical manufacturing supply chains.

Contrast media intermediates are used in the supply chain for diagnostic imaging products. The project is also intended to strengthen Blue Jet's CDMO capabilities, where manufacturers support pharmaceutical innovators through development and production services.

The proposed plant has been described as having production capacity of around 2,000 kilolitres for APIs and specialty intermediates. As the unit will be developed in phases, the reported long-term capacity and investment plans depend on the project's subsequent approvals and execution milestones.

What are the key investment and employment details?

The project carries a long-term investment potential of up to ₹2,300 crore, while Blue Jet has initially approved around ₹1,000 crore for the first phase. It is expected to create 1,750 direct jobs and about 250 indirect jobs, taking the indicated employment impact to around 2,000 positions.

The employment projections are linked to the project reaching its planned scale. Government statements have presented the investment as an addition to the industrial base of the Visakhapatnam-Anakapalli economic region, where pharmaceutical manufacturing and specialty chemical activity are being promoted.

Why does the project matter for pharmaceutical manufacturing?

The Rambilli project matters because it targets higher-value pharmaceutical intermediates, APIs and specialty chemical products rather than a single product line. Its CDMO orientation may allow Blue Jet to support global pharmaceutical innovators that require specialised development and manufacturing capabilities.

India's pharmaceutical industry relies on manufacturing networks that include bulk drugs, intermediates, APIs and finished formulations. Investments in intermediates and complex chemistry can broaden domestic manufacturing capabilities within these supply chains. The source material positions the project as part of India's effort to strengthen its role in global pharmaceutical supply chains.

Blue Jet was founded in 1968 as Jet Chemicals and is headquartered in Maharashtra. The company has developed into an integrated CDMO, and the Andhra Pradesh facility is planned as a further expansion of this business model.

How could the project affect the Visakhapatnam-Anakapalli region?

The project is expected to add manufacturing activity and employment in the Visakhapatnam-Anakapalli corridor, with 1,750 direct and around 250 indirect jobs projected once the facility reaches its intended scale. The project may also require supporting infrastructure and services associated with a large pharmaceutical manufacturing site.

Nara Lokesh described the facility as an important development for North Andhra and said the state had allotted land and focused on infrastructure at the industrial park. The stated policy objective is to build a stronger pharmaceutical ecosystem and increase the state's drug-manufacturing presence.

For investors, the immediate financial reference point is the ₹1,000 crore initial Phase 1 approval rather than the entire ₹2,300 crore potential investment. The remaining investment is conditional on approvals, milestones and further decisions by Blue Jet's board.

Conclusion

Blue Jet's Rambilli facility represents a planned ₹2,300 crore addition to Andhra Pradesh's pharmaceutical and specialty chemical manufacturing base. The 102.48-acre project combines complex intermediates, APIs, sweeteners and multipurpose chemistry, while the projected 2,000 total direct and indirect jobs give it regional industrial significance.

The next point to watch is execution of Phase 1, for which approximately ₹1,000 crore has been approved. Investors and local stakeholders will also track regulatory clearances, further board approvals, construction progress and whether the facility begins operations within the FY2028-29 target period.